ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 7.370-7.640 for the period, compared to the consensus EPS estimate of 6.970. The company issued revenue guidance of $854.0 million-$873.0 million, compared to the consensus revenue estimate of $869.3 million. ANI Pharmaceuticals also updated its FY 2026 guidance to EPS.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Guggenheim lifted their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

ANI Pharmaceuticals Trading Down 5.9%

ANI Pharmaceuticals stock opened at $76.28 on Monday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The stock has a market cap of $1.71 billion, a PE ratio of 46.80 and a beta of 0.51. The stock has a 50-day moving average of $82.81 and a two-hundred day moving average of $83.29. ANI Pharmaceuticals has a one year low of $52.74 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals’s revenue was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, research analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 8,643 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the sale, the director owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. The trade was a 12.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Krista Davis sold 1,622 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $82.40, for a total value of $133,652.80. Following the sale, the senior vice president owned 58,564 shares in the company, valued at approximately $4,825,673.60. The trade was a 2.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,601 shares of company stock worth $2,410,898 over the last 90 days. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ANIP. UBS Group AG boosted its position in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $32,992,000. Rubric Capital Management LP boosted its holdings in ANI Pharmaceuticals by 33.3% during the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock worth $31,457,000 after buying an additional 85,745 shares in the last quarter. Balyasny Asset Management L.P. grew its position in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after buying an additional 276,233 shares during the period. Finally, Nomura Holdings Inc. grew its position in ANI Pharmaceuticals by 347.3% during the third quarter. Nomura Holdings Inc. now owns 195,518 shares of the specialty pharmaceutical company’s stock valued at $17,909,000 after buying an additional 151,805 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.